Physician profile
Javier E Espinoza
NPI 1508002262
$6,752.67
in general payments reported to CMS, 2019-2025
26 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what 86% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,210 · 2022: $1,491 · 2023: $1,653 · 2024: $1,177 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,991 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.01 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,369.24 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,138.57 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $880.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $775.67 | 2022-2025 | Freestyle Libre 3, Proclaim |
| Abbvie INC. | $481.45 | 2021-2025 | |
| Pfizer INC. | $400.90 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.53 | 2021-2024 | Synjardy, Jardiance |
| Amgen INC. | $235.81 | 2021-2025 | Evenity, Prolia, Otezla |
| Glaxosmithkline, LLC. | $199.38 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $179.11 | 2021-2022 | |
| Medtronic, INC. | $136.40 | 2022 | |
| Sanofi-Aventis U.S. LLC | $121.42 | 2021-2023 | |
| Exact Sciences Corporation | $105.27 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $73.06 | 2023 | |
| Merck Sharp & Dohme LLC | $64.37 | 2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $62.76 | 2022 | |
| Astellas Pharma US INC | $61.00 | 2023 | |
| Arbor Pharmaceuticals, INC. | $49.96 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.31 | 2025 | Eliquis |
| Eisai INC. | $20.09 | 2021 | |
| Biogen, INC. | $19.75 | 2021 | |
| Dexcom, INC. | $19.09 | 2022 | |
| Genentech USA, INC. | $18.68 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.84 | 2021 | |
| Janssen Pharmaceuticals, INC | $16.08 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Espinoza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.